

Introduction to Drug Law April 27-28 FDLI

> Frederick R. Ball Duane Morris LLP

©2017 Duane Morris LLP. All Rights Reserved. Duane Morris is a registered service mark of Duane Morris LLP.

Duane Morris – Firm Offices | New York | London | Singapore | Philadelphia | Chicago | Washington, D.C. | San Francisco | Silicon Valley | San Diego | Los Angeles | Taiwan | Boston | Houston | Hou



General Disclaimers

- Any Opinion Expressed in here is mine and neither FDLI's nor Duane Morris's
- Nothing in here constitutes legal advise
- I am not your lawyer
- Please ask questions If I know the answer I provide. If not, I will make something up



- Jurisdiction
 - Presumed
 - Includes drugs not already in the United States





- Prohibited Acts
 - Adulterated
 - Misbranded
 - Unapproved new drugs
 - Wholesale distribution without proper licensure or registration
 - Failure to implement approved risk evaluation and mitigation strategy
 - Off-label promotion
 - Diversion
 - Fraudulent Price Reporting
 - Others





Violations

- Adulteration
 - Not compliant with good manufacturing practices ("CGMP")
 - Strength, quality, purity
 - Mixed, packed improperly





Violations

- Misbranding
 - Labeling
 - Very broad





Violations

- Unapproved "New" Drugs
 - Drug or Biologic
 - Does Not Comply With NDA, ANDA, Biologics License
- No NDA, ANDA, Biologics License
- OTC Drugs No Compliant Monograph, NDA, or ANDA





- Wholesale Distribution
 - 21 U.S.C. § 353(e)
 - Required to be licensed in a state
 - United States v. Segredo
 - State requirements
 - Most require out of state wholesalers/manufacturers/distributors to register
 - Colorado, Indiana, other states
 - Verified Accredited Wholesale Distributors (VAWD) inspection or state inspection last two years
 - Many states separate Registration for Controlled Substances



- Risk Evaluation and Mitigation Strategy (REMS) containing Elements to Assure Safe Use (ETASU)
- Secretary can require
 - Pre-Approval
 - Post-Approval



- Off label promotion
 - Caputo
 - Allergan
 - Caronia
- Metatags
- Social Media
- Safe Harbor Distribution peer reviewed articles



- Diversion
- DEA
- Reporting requirements



- Inspections
 - 21 U.S.C. 374
- VAI
- FDA Form 483
 - Not final agency action
 - Pattern of Conduct
 - Repeated Violations
 - Written Response 15 business days
 - Follow-on Responses





CTP -- Compliance Check Inspections

- Undercover Retailer Buy Inspections
- Trained Minor
- Results Sent to FDA
- Violation?
- 1st time WL
- 2nd Time WL, CMP, No Tobacco Sale Order
- Results Posted FDA website

CTP CMPs

- Number of Regulation Violations CMP Amount
- 1 \$0 (CTP will send a Warning Letter)
- 2 within a 12-month period \$320
- 3 within a 24-month period \$638
- 4 within a 24-month period \$2,559
- 5 within a 36-month period \$6,397
- 6 within a 48-month period \$12,794



CTP - No Tobacco Sale Orders

- 5 or more violations in 36 months
- Complaint
 - Settlement
 - Hearing before and ALJ



- Warning letters
 - Not final agency action
 - Regional Offices
 - Written Response(s)
- Import Alerts (Detain without Inspection)
- Establishment Inspection Report



Inspections-Risk Based

- "Any establishment"
- Regular business hours
- "All things therein," "adulterated or misbranded"
- Not financial data or sales data except in limited situations
- Have person in charge
- Photos or video?
- Questioning by FDA



- Voluntary recalls
 - Not really voluntary
 - Shadow Recall



- Conducting a recall
 - Plan in place
 - Level (i.e. to whom to send notice)
 - > Follow-up
 - Tracking
 - Post-Receipt handling
 - Media
 - FDA Input



- Civil penalties / disgorgements
 - Fines
 - Profit disgorgement
 - Contempt
 - > Civil
 - > Criminal



- Civil seizures
 - In rem
 - Supplemental Rules of Civil Procedure (Rules of Admiralty)
 - FDA or DEA must provide timely notice
 - You must assert claim
 - Potential counter-claims
 - > Fees
 - Value of Product





Expiration date may moot claim





- Injunctions
 - Temporary restraining orders
 - Preliminary & Permanent injunctions
 - Consent decrees
 - Deferred prosecution agreements
 - Ongoing monitoring
 - Contempt
 - > Civil
 - > Criminal



- Criminal prosecutions
 - Strict liability
 - Knowing vs. unknowing
 - Responsible person U.S. v. Park
 - The *Park* doctrine provides for criminal liability (first-time misdemeanor and possible subsequent felony) under the FDCA without proof that a corporate official acted with intent (even negligence) or knowledge. Factors are:
 - The corporate official's knowledge of and actual participation in the violation;
 - Whether the violation involves actual or potential harm to the public;
 - Whether the violation is obvious or reflects a pattern of illegal behavior and/or failure to heed prior warnings;
 - Whether the violation is widespread or serious;
 - The quality of the legal and factual support for the proposed prosecution; and
 - Whether the proposed prosecution is a prudent use of FDA resources.





- Criminal prosecutions (Cont.)
 - Potentially responsible for actions of contractors if acting on your behalf
 - Debarment
 - Exclusion





Other Issues

- Federal Trade Commission
 - Marketing Issues
 - False Advertising
 - Reverse Payments
- False Claims Act
 - Federal
 - State
 - Criminal and civil
 - Fines per claim



Other Issues

- Foreign Corrupt Practices Act
 - Reporting Requirements
 - Bribing foreign officials
- Sunshine Act
 - Reporting Requirements